4-(2,1-benzoxazol-3-yl)-2-fluoro-N-(8-methylisoquinolin-1-yl)-N-[(3R)-piperidin-3-yl]benzamide
C29H25FN4O2 — CID 172532634
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-(2,1-benzoxazol-3-yl)-2-fluoro-N-(8-methylisoquinolin-1-yl)-N-[(3R)-piperidin-3-yl]benzamide
4-(2,1-benzoxazol-3-yl)-2-fluoro-N-(8-methylisoquinolin-1-yl)-N-[(3R)-piperidin-3-yl]benzamide (PubChem CID 172532634) has the molecular formula C29H25FN4O2 and a molecular weight of 480.54 g/mol. Its IUPAC name is 4-(2,1-benzoxazol-3-yl)-2-fluoro-N-(8-methylisoquinolin-1-yl)-N-[(3R)-piperidin-3-yl]benzamide.
Molecular Properties
| Compound Name | 4-(2,1-benzoxazol-3-yl)-2-fluoro-N-(8-methylisoquinolin-1-yl)-N-[(3R)-piperidin-3-yl]benzamide |
|---|---|
| PubChem CID | 172532634 |
| Molecular Formula | C29H25FN4O2 |
| Molecular Weight | 480.54 g/mol |
| Exact Mass | 480.20 |
| IUPAC Name | 4-(2,1-benzoxazol-3-yl)-2-fluoro-N-(8-methylisoquinolin-1-yl)-N-[(3R)-piperidin-3-yl]benzamide |
| SMILES | Cc1cccc2ccnc(N(C(=O)c3ccc(-c4onc5ccccc45)cc3F)[C@@H]3CCCNC3)c12 |
| InChI | InChI=1S/C29H25FN4O2/c1-18-6-4-7-19-13-15-32-28(26(18)19)34(21-8-5-14-31-17-21)29(35)22-12-11-20(16-24(22)30)27-23-9-2-3-10-25(23)33-36-27/h2-4,6-7,9-13,15-16,21,31H,5,8,14,17H2,1H3/t21-/m1/s1 |
| InChIKey | RDIJLQGELWCANI-OAQYLSRUSA-N |
| XLogP | 5.89 |
| TPSA | 71.26 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 36 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 480.54 |
| LogP ≤ 5 | 5.89 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 172532634 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.